Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

• Váldodahkkit: Chang Chen (Dahkki), Yi Zhang (Dahkki), Jianying Huang (Dahkki), Ping Yin (Dahkki), Zhenshun Cheng (Dahkki), Jianyuan Wu (Dahkki), Song Chen (Dahkki), Yongxi Zhang (Dahkki), Bo Chen (Dahkki), Mengxin Lu (Dahkki), Yongwen Luo (Dahkki), Lingao Ju (Dahkki), Jingyi Zhang (Dahkki), Xinghuan Wang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2021-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: In addition to supportive therapy, antiviral therapy is an effective treatment for coronavirus disease 2019 (COVID-19).Objective: To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients.Methods: We conducted a prospective, randomized, control...